Home › Research › Inflammation and the immune system
The Prevention of Fatal Tauopathy in a Mouse Model of Alzheimer Disease by Blocking BCL2
Gerard J. Nuovo, Madison Rice, Nicola A. O. Zanesi, Dwitiya B. Sawant, Candice J. Crilly, Esmerina Tili. Applied immunohistochemistry & molecular morphology, 2025-02-11
Topic: Brain proteins, microglia and lab models
Plain-language summary
A major goal in Alzheimer disease (AD) research is the reduction of the abnormal tau burden. Using multispectral analyses on brain tissues from humans who died of AD it was documented that neurons with hyperphosphorylated tau protein accumulate many proteins of the BCL2 family, including those that block cell turnover (eg, BCL2, MCL1, BCLXL) and those that promote cell turnover (eg, NOXA, PUMA, BAK, BAX). A mouse model of AD with the humanized hyperphosphorylated tau protein was used to test the hypothesis that shifting this balance to a pro-cell turnover milieu would reduce the tau burden with concomitant clinical improvement. Here, we show that a mouse model of AD with death at 11 to 15 months due to CNS tauopathy had a marked reduction in the tau burden after treatment with the FDA-approved drug venetoclax, which blocks BCL2. The reduction of the number of target neurons positive for hyperphosphorylated tau protein after venetoclax treatment in the brain and spinal cord neurons was 94.5% as determined by immunohistochemistry and 98.1% as documented with the modified Bielchowsky stain. The venetoclax treatment began after documented neurofibrillary tangles (NFTs) were evident and there was a concomitant reduction in neuroinflammation. The treated mice were robust until sacrificed at 13 months as compared with the untreated mice that showed unequivocal evidence of brain and spinal cord damage both clinically and at autopsy. We conclude that otherwise inexorable abnormal tau protein deposition, even after initiation, can be prevented by a drug that blocks one anti-cell turnover protein abundant in the NFTs of human AD.
What this study adds
Evidence grade: Low
In a mouse model of Alzheimer's disease with humanized hyperphosphorylated tau, the FDA-approved drug venetoclax, which blocks BCL2, markedly reduced the tau burden and neuroinflammation and kept treated mice robust until sacrifice. Reported effect size: 94.5%; 98.1%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nuovo, G. J., Rice, M., Zanesi, N. A. O., Sawant, D. B., Crilly, C. J., & Tili, E. (2025). The Prevention of Fatal Tauopathy in a Mouse Model of Alzheimer Disease by Blocking BCL2. Applied immunohistochemistry & molecular morphology. https://doi.org/10.1097/pai.0000000000001251
Vancouver
Nuovo GJ, Rice M, Zanesi NAO, Sawant DB, Crilly CJ, Tili E. The Prevention of Fatal Tauopathy in a Mouse Model of Alzheimer Disease by Blocking BCL2. Applied immunohistochemistry & molecular morphology. 2025. doi:10.1097/pai.0000000000001251. PMID: 39931956.
BibTeX
@article{nuovo2025-39931956,
author = {Nuovo, Gerard J. and Rice, Madison and Zanesi, Nicola A. O. and Sawant, Dwitiya B. and Crilly, Candice J. and Tili, Esmerina},
title = {{The Prevention of Fatal Tauopathy in a Mouse Model of Alzheimer Disease by Blocking BCL2}},
journal = {Applied immunohistochemistry \& molecular morphology},
year = {2025},
doi = {10.1097/pai.0000000000001251},
pmid = {39931956},
url = {https://doi.org/10.1097/pai.0000000000001251}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The treated mice were robust until sacrificed at 13 months as compared with the untreated mice that showed unequivocal evidence of brain and spinal cord damage both clinically and at autopsy.
- We conclude that otherwise inexorable abnormal tau protein deposition, even after initiation, can be prevented by a drug that blocks one anti-cell turnover protein abundant in the NFTs of human AD.
Why it matters
In a mouse model of Alzheimer's disease with humanized hyperphosphorylated tau, the FDA-approved drug venetoclax, which blocks BCL2, markedly reduced the tau burden and neuroinflammation and kept treated mice robust until sacrifice. This is animal research, so it does not yet show that blocking BCL2 prevents tauopathy in people.
Study details
- Effect size94.5%; 98.1%
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Applied immunohistochemistry & molecular morphology) |
| Journal's citation record | 1 / 4 | Applied immunohistochemistry & molecular morphology: journal h-index 75 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “mouse”) — scores zero |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Esmerina Tili: h-index 33 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The Ohio State University: institution h-index 1,378 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39931956) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Inflammation and the immune system from nearby years
Also tagged “phosphorylated”
733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.